Importance Oral anthelmintic niclosamide has potent in vitro antiviral activity against SARS-
CoV-2. Repurposed niclosamide could be a safe and efficacious COVID-19 therapy …

Background Coronavirus disease 19 (COVID-19) is spreading globally and treatment
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …

SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the
great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 …

The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for
therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an …

Background COVID-19 pandemic has ignited the urge for repurposing old drugs as
candidate antiviral medicines to treat novel challenges of viral infections. Niclosamide (NCS) …

Vaccines have reduced the transmission and severity of COVID‐19, but there remains a
paucity of efficacious treatment for drug‐resistant strains and more susceptible individuals …

Aim/purpose Niclosamide (NCL) is an anthelminthic drug, which is widely used to treat
various diseases due to its pleiotropic anti-inflammatory and antiviral activities. NCL …

Abstract Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world
wide as of 25 March 2020 and posing a serious threat to public health. There is a need …

There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …

Background: In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction
in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk …